Nektar Therapeutics Raises $115 Million Through Secondary Offering to Fund Pipeline Development
Key Insights
Nektar Therapeutics completed a secondary stock offering of 4.89 million shares at $23.50 per share, raising approximately $115 million in gross proceeds.
The capital raise resulted in significant dilution for existing shareholders, increasing the company's outstanding shares from 12.4 million to over 17 million.
Funds will support general corporate purposes including drug development and manufacturing, with the company's lead candidate rezpegaldesleukin showing positive results for moderate-to-severe atopic dermatitis (search).
Nektar Therapeutics completed a secondary stock offering worth approximately $115 million, selling 4.89 million shares at $23.50 each to fund its clinical pipeline development. The clinical-stage biotechnology company announced the completion of the share flotation after market hours on Wednesday, with underwriters fully exercising their option to purchase an additional 638,298 shares.
The capital raise represents a significant dilution event for existing shareholders, expanding the company's outstanding share count from approximately 12.4 million to over 17 million shares. This nearly 40% increase in share count contributed to a 3% decline in stock price on Thursday, contrasting with the broader S&P 500 index's 0.8% gain.
Funding Strategic Priorities
Nektar stated it plans to deploy the new capital for "general corporate purposes," which may include drug development and manufacturing activities, as well as research and development initiatives. The funding comes as the company advances multiple pipeline projects, with its lead candidate rezpegaldesleukin recently demonstrating positive results in treating moderate-to-severe atopic dermatitis (search).
Market Response and Dilution Concerns
The secondary offering follows a common pattern in the biotech sector, where cash-hungry companies frequently turn to equity markets for funding. However, the substantial increase in share count has raised investor concerns about potential future dilution events, as the company continues to advance its clinical programs without generating revenue from approved products.
The market's negative reaction reflects broader investor wariness about dilutive financing in the biotech space, particularly when companies significantly expand their share base. While Nektar's pipeline shows promise with multiple development projects, the immediate impact on existing shareholders remains a key concern for the investment community.